Advertisement
U.S. markets closed

Orexo AB (publ) (ORXOY)

Other OTC - Other OTC Delayed Price. Currency in USD
1.37000.0000 (0.00%)
At close: 10:15AM EDT

Orexo AB (publ)

Rapsgatan 7E
Uppsala
Sweden
46 1 87 80 88 00
https://www.orexo.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees116

Key Executives

NameTitlePayExercisedYear Born
Mr. Nikolaj SorensenPresident & CEO5.78MN/A1972
Mr. Fredrik JarrstenExecutive VP & CFON/AN/A1967
Ms. Cecilia CouplandSenior VP & Head of OperationsN/AN/A1976
Lena WangeInvestor Relations & Communications DirectorN/AN/AN/A
Mr. Robert RonnSenior VP and Head of R&DN/AN/A1976
Dr. Edward Kim M.B.A., M.D.Chief Medical OfficerN/AN/AN/A
Mr. Robert A. DelucaPresident of Orexo US IncN/AN/A1961
Mr. Jesper LindAdvisorN/AN/A1960
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.

Corporate Governance

Orexo AB (publ)’s ISS Governance QualityScore as of March 1, 2024 is 5. The pillar scores are Audit: 8; Board: 1; Shareholder Rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.